Published in J Virol on May 01, 2006
Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A (2009) 2.08
Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines (2009) 1.83
Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One (2009) 1.82
Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. Int Rev Immunol (2009) 1.13
Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity. J Virol (2008) 1.05
Quantitative review of antibody response to inactivated seasonal influenza vaccines. Influenza Other Respir Viruses (2011) 0.97
Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine (2009) 0.96
A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study. Am J Clin Oncol (2008) 0.88
The adjuvant LT-K63 can restore delayed maturation of follicular dendritic cells and poor persistence of both protein- and polysaccharide-specific antibody-secreting cells in neonatal mice. J Immunol (2012) 0.85
Chitosan: a promising safe and immune-enhancing adjuvant for intranasal vaccines. Hum Vaccin Immunother (2013) 0.85
Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans. Vaccine (2009) 0.84
Robust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coli. PLoS One (2012) 0.83
Influenza vaccines: a moving interdisciplinary field. Viruses (2014) 0.81
Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice. PLoS One (2013) 0.81
Immunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration. Clin Vaccine Immunol (2012) 0.81
Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. Protein Cell (2015) 0.78
Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection. Vaccines (Basel) (2016) 0.77
Vaccines for an influenza pandemic: scientific and political challenges. Influenza Other Respir Viruses (2007) 0.76
Vaccination with Killed but Metabolically Active E. coli Over-expressing Hemagglutinin Elicits Neutralizing Antibodies to H1N1 Swine Origin Influenza A Virus. J Nat Sci (2017) 0.75
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med (1998) 6.75
Influenza. Lancet (1999) 4.77
Determinants of immunity to influenza infection in man. Br Med Bull (1979) 4.62
Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med (2004) 4.10
Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol (1986) 3.33
Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol (2001) 3.05
Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol (1986) 2.67
Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine (2002) 2.47
Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol (2000) 2.06
Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun (1997) 2.05
Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine (2003) 1.78
Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol Today (1999) 1.74
Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum. J Clin Microbiol (1987) 1.53
Distribution and removal of human serum albumin-technetium 99m instilled intranasally. Br J Clin Pharmacol (1976) 1.52
Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine (2001) 1.49
Mucosal immunity to influenza without IgA: an IgA knockout mouse model. J Immunol (1999) 1.29
Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J Infect Dis (1998) 1.18
Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev Vaccines (2003) 1.13
Influenza vaccines: present and future. Adv Virus Res (1999) 1.08
Intranasal drug delivery by spray and drops. J Pharm Pharmacol (1985) 1.04
A clinical trial of WRL 105 strain live attenuated influenza vaccine comparing four methods of intranasal vaccination. J Hyg (Lond) (1976) 1.02
Molecular analysis of an outbreak of influenza in the United Kingdom. Eur J Epidemiol (1997) 1.01
Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine. Vaccine (2003) 0.99
Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine (1996) 0.99
Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. Vaccine (2003) 0.97
Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine (2003) 0.96
Local and systemic immune response in community-dwelling elderly after intranasal or intramuscular immunization with inactivated influenza vaccine. J Med Virol (2000) 0.92
Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J Virol (1999) 0.92
Healthcare workers and their attitudes to influenza vaccination. Commun Dis Public Health (2002) 0.91
Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles. Infect Immun (2002) 0.90
Reduced infectivity of cold-adapted influenza A H1N1 viruses in the elderly: correlation with serum and local antibodies. J Am Geriatr Soc (1992) 0.88
Evaluation of cold-adapted, reassortant influenza B virus vaccines in elderly and chronically ill adults. J Infect Dis (1994) 0.88
Mucosal immune responses to pneumococcal polysaccharides: implications for vaccination. Trends Microbiol (1995) 0.81
Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice. Vaccine (1994) 0.79
Is there a role for a mucosal influenza vaccine in the elderly? Drugs Aging (1999) 0.79
Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med (2010) 9.90
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity (2009) 8.20
A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med (2006) 7.87
Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol (2010) 6.64
Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet (2003) 6.52
Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med (2009) 5.73
Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet (2006) 5.72
Evidence for several waves of global transmission in the seventh cholera pandemic. Nature (2011) 5.62
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol (2010) 4.75
Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet (2005) 4.16
Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet (2009) 3.97
Cholera due to altered El Tor strains of Vibrio cholerae O1 in Bangladesh. J Clin Microbiol (2006) 3.60
TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol (2006) 3.44
Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis (2005) 3.20
Infection of human airway epithelium by human and avian strains of influenza a virus. J Virol (2006) 3.02
Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis (2008) 2.93
5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis (2013) 2.82
Sudden acute respiratory syndrome. BMJ (2003) 2.68
Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. Vaccine (2006) 2.49
Mucosal FOXP3-expressing CD4+ CD25high regulatory T cells in Helicobacter pylori-infected patients. Infect Immun (2005) 2.33
CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol (2009) 2.30
Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med (2008) 2.21
Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med (2002) 2.20
A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers. Mult Scler (2012) 2.16
Hepatitis C virus-specific Th17 cells are suppressed by virus-induced TGF-beta. J Immunol (2008) 2.04
Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine (2003) 2.04
[Reply on new drugs against type 2 diabetes: important to gain experience and knowledge]. Lakartidningen (2008) 2.03
Caspase-1-processed cytokines IL-1beta and IL-18 promote IL-17 production by gammadelta and CD4 T cells that mediate autoimmunity. J Immunol (2011) 1.98
Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology. J Immunol (2003) 1.96
Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun (2010) 1.93
Clinical and laboratory features distinguishing pandemic H1N1 influenza-related pneumonia from interpandemic community-acquired pneumonia in adults. Thorax (2011) 1.91
Molecular diagnosis of influenza. Rev Med Virol (2002) 1.90
Reproducibility of serologic assays for influenza virus A (H5N1). Emerg Infect Dis (2009) 1.88
Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases. Trends Immunol (2002) 1.85
Characterization of human CD25+ CD4+ T cells in thymus, cord and adult blood. Immunology (2002) 1.81
Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol (2006) 1.81
Innate immune responses of human neonatal cells to bacteria from the normal gastrointestinal flora. Infect Immun (2002) 1.79
MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One (2009) 1.79
A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J Virol (2003) 1.76
Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet (2003) 1.75
Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl Trop Dis (2011) 1.73
Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine (2007) 1.72
CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons. J Infect Dis (2002) 1.69
Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis (2004) 1.66
IL-17-producing γδ T cells and innate lymphoid cells. Eur J Immunol (2012) 1.66
Targeting regulatory T cells in cancer. Cancer Res (2011) 1.66
Hepatitis C virus non-structural protein 4 suppresses Th1 responses by stimulating IL-10 production from monocytes. Eur J Immunol (2003) 1.60
HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med (2002) 1.59
A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS One (2008) 1.57
Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies. Antivir Ther (2008) 1.55
Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog (2013) 1.54
Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine (2008) 1.52
Oral tolerance induction with antigen conjugated to cholera toxin B subunit generates both Foxp3+CD25+ and Foxp3-CD25- CD4+ regulatory T cells. J Immunol (2006) 1.52
CD200 ligand receptor interaction modulates microglial activation in vivo and in vitro: a role for IL-4. J Neurosci (2007) 1.51
Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. J Immunol (2009) 1.49
Inflammasome activation by adenylate cyclase toxin directs Th17 responses and protection against Bordetella pertussis. J Immunol (2010) 1.48
Influence of gastrointestinal commensal bacteria on the immune responses that mediate allergy and asthma. J Allergy Clin Immunol (2011) 1.47
Retinoic acid expression associates with enhanced IL-22 production by γδ T cells and innate lymphoid cells and attenuation of intestinal inflammation. J Exp Med (2013) 1.47
Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasome-independent block of angiogenesis and matrix metalloproteinases. Int J Cancer (2011) 1.45
Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS (2003) 1.45
Differences between asthmatics and nonasthmatics hospitalised with influenza A infection. Eur Respir J (2012) 1.44
Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine (2006) 1.43
Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children. Vaccine (2005) 1.40
Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine (2008) 1.40
Predictors of clinical outcome in a national hospitalised cohort across both waves of the influenza A/H1N1 pandemic 2009-2010 in the UK. Thorax (2012) 1.40
Depletion of NK cells results in disseminating lethal infection with Bordetella pertussis associated with a reduction of antigen-specific Th1 and enhancement of Th2, but not Tr1 cells. Eur J Immunol (2004) 1.39
Infection with a helminth parasite attenuates autoimmunity through TGF-beta-mediated suppression of Th17 and Th1 responses. J Immunol (2009) 1.39
Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International Standard. Vaccine (2011) 1.37
Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J (2009) 1.36
Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg Infect Dis (2005) 1.36
Pattern of cytokine responses to gram-positive and gram-negative commensal bacteria is profoundly changed when monocytes differentiate into dendritic cells. Infect Immun (2004) 1.35
Broad up-regulation of innate defense factors during acute cholera. Infect Immun (2007) 1.32
Inhibition of ERK MAPK suppresses IL-23- and IL-1-driven IL-17 production and attenuates autoimmune disease. J Immunol (2009) 1.32
Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arterioscler Thromb Vasc Biol (2010) 1.31
Cholera toxin - a foe & a friend. Indian J Med Res (2011) 1.31
Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. Curr Opin Immunol (2005) 1.31
Lack of interleukin-1 receptor I (IL-1RI) protects mice from high-fat diet-induced adipose tissue inflammation coincident with improved glucose homeostasis. Diabetes (2011) 1.30
Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis (2009) 1.27
Adenylate cyclase toxin from Bordetella pertussis synergizes with lipopolysaccharide to promote innate interleukin-10 production and enhances the induction of Th2 and regulatory T cells. Infect Immun (2004) 1.25
Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J Immunol (2008) 1.25
B lymphocytes promote expansion of regulatory T cells in oral tolerance: powerful induction by antigen coupled to cholera toxin B subunit. J Immunol (2008) 1.25
Activation of p38 plays a pivotal role in the inhibitory effect of lipopolysaccharide and interleukin-1 beta on long term potentiation in rat dentate gyrus. J Biol Chem (2003) 1.24
Cholera toxin promotes the induction of regulatory T cells specific for bystander antigens by modulating dendritic cell activation. J Immunol (2003) 1.24
Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. Inflamm Bowel Dis (2006) 1.22